TTUHSC School of Medicine
HomeSchool of MedicineInternal MedicineFellowship Programs

Internal Medicine

CLINICAL TRIALS

1991 Head of Cancer Clinical Research for TTUHSC; PI for SWOG, GOG, NSABP and various Pharmaceutical trials. Since 1991, Dr. Cobos has been the PI or CO-PI in over 100 clinical trials.

OPEN

L-MICRO - IDENTIFICATION OF NOVEL TUMOR PROTEINS FOR TUMOR BIOLOGY RESEARCH IN SOLID AND HEMATOLOGICAL MALIGNANCIES

NMDP RESEARCH DATABASE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND MARROW TOXIC INJURIES

INJURIES

NATIONAL MARROW DONOR PROGRAM- PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND MARROW TOXIC INJURIES

S0221-PHASE III TRIAL OF CONTINUOUS SCHEDULE AC + G VS. 2 WEEK SCHEDULE AC, FOLLOWED BY PACLITAXEL GIVEN EITHER EVERY 2 WEEKS OR WEEKLY FOR 12 WEEKS AS POST-OPERATIVE ADJUVANT THERAPY IN NODE-POSITIVE OR HIGH-RISK NODE NEGATIVE BREAST CANCER

(PACCT-1):PROGRAM FOR THE ASSESSMENT OF CLINICAL CANCER TESTS TRIAL ASSIGNING INDIVIDUALIZED OPTIONS FOR TREATMENT: THE TAILORX TRIAL

P-54 - PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH MALIGNANT SOLID TUMORS

P-42 - PHASE I TRIAL OF INTRAVENOUS FENRETINIDE (4-HPR) FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES

PHASE IIB, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS INTENSIVE SALVAGE THERAPY IN ADULT PATIENTS = 65 YEARS OLD WITH AML IN FIRST SALVAGE THERAPY IN FIRST RELAPSE FOLLOWING AN INITIAL CR > 1 MONTH DURATION -(CLTR0308 - 205)

ABT4710N: A PHASE II MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF THE SAFETY, EFFICACY AND PHARMACOKINETICS OF ABT-263 IN COMBINATION WITH DOSE-INTENSIVE RITUXIMAB, OR DOSE-INTENSIVE RITUXIMAB ALONE, RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH B-CELL, CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

C 80405 - A PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN OR OXALIPLATIN/5-FU/LEUCOVORIN WITH BEVACIZUMAB OR CETUXIMAB (C225) FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM

FOLLOW-UP

AVENTIS ITP - A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, ACTIVELY-CONTROLLED, PARALLEL GROUP STUDY ON THE EFFICACY AND SAFETY OF LIQUID IMMUNE GLOBULIN INTRAVENOUS (HUMAN) CE1160 10%, COMPARED TO IMMUNE GLOBULIN INTRAVENOUS (HUMAN) GAMIMUNE N, 10% IN SUBJECTS WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

GOG 0175 - A RANDOMIZED PHASE III TRIAL OF IV CARBOPLATIN (AUC6) AND PACLITAXEL 175MG/M2 Q 21 DAYS X 3 COURSES PLUS LOW DOSE PACLITAXEL 40 MG/M2/WK VERSUS IV CARBOPLATIN (AUC 6) AND PACLITAXEL 175 MG/M2 Q 21 DAYS X 3 COURSES PLUS OBSERVATION IN PATIENTS WITH EARLY STAGE OVARIAN CARCINOMA

SWOG 9410 DOXORUBICIN DOSE ESCALATION, WITH OR WITHOUT TAXOL, AS PART OF THE CA ADJUVANT CHEMOTHERAPY REGIMEN FOR NODE POSITIVE BREAST CANCER: A PHASE III INTERGROUP STUDY

GOG 158 A PHASE III RANDOMIZED STUDY OF CISPLATIN AND PACLITAXEL (24-HOUR INFUSION) VERSUS CARBOPLATIN AND PACLITAXEL (3-HOUR INFUSION) IN OPTIMAL STAGE III EPITHELIAL OVARIAN CARCINOMA.

GOG 157 A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN (AUC 7.5) AND PACLITAXEL 175MG/M2Q21 DAYS X 3 COURSES VS. THE SAME REGIMEN X6 COURSES, IN PATIENTS WITH SELECTED STAGE IC AND II (A, B, C) AND SELECTED IA AND IB OVARIAN CANCER

SWOG-9704 A RANDOMIZED PHASE III TRIAL COMPARING EARLY HIGH DOSE CHEMORADIOTHERAPY AND AN AUTOLOGOUS STEM CELL TRANSPLANT TO CONVENTIONAL DOSE CHOP CHEMOTHERAPY (WITH POSSIBLE LATE AUTOLOGOUS STEM CELL TRANSPLANT) FOR PATIENTS WITH DIFFUSE AGGRESSIVE NON-HODGKIN'S LYMPHOMA IN THE HIGH-INTERMEDIATE AND HIGH RISK INTERNATIONAL CLASSIFICATION PROGNOSTIC GROUPS.

ECOG 2197 PHASE III STUDY OF ADRIAMYCIN/TAXOTERE VS. ADRIAMYCIN/CYOXAN FOR THE ADJUVANT TREATMENT OF NODE POSITIVE OR HIGH RISK NODE NEGATIVE BREAST CANCER

A PHASE III ADJUVANT TRIAL OF SEQUENCED EC + FILGRASTIM + EPOETIN ALFA FOLLOWED BY PACLITAXEL VERSUS SEQUENCED AC FOLLOWED BY PACLITAXEL VERSUS CEF AS THERAPY FOR PREMENOPAUSAL WOMEN AND EARLY POSTMENOPAUSAL WOMEN WHO HAVE HAD POTENTIALLY CURATIVE SURGERY FOR NODE POSITIVE OR HIGH RISK NODE NEGATIVE BREAST CANCER

E 2496 - A RANDOMIZED PHASE III TRIAL OF ABVD VS. STANFORD V WITH OR WITHOUT RADIATION THERAPY IN LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKIN'S DISEASE

NSABP C-08A PHASE III CLINICAL TRIAL COMPARING INFUSIONAL 5-FLUOROURACIL (5-FU), LEUCOVORIN, AND OXALIPLATIN (MFOLFOX6)EVERY TWO WEEKS WITH BEVACIZUMAB TO THE SAME REGIMEN WITHOUT BEVACIZUMAB FOR THE TREATMENT OF PATIENTS WITH RESECTED STAGES II AND III CARCINOMA OF THE COLON

COMPASSIONATE USE PROTOCOL FOR THE USE OF AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS FOR COLLECTION AND TRANSPLANTATION

A RANDOMIZED PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5- FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER ( PFIZER - A6181104)

COMPLETED

*EN3267-007 - A MULTIPLE-DOSE, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF EN3267 IN THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS

*SCHERING-PLOUGH - A PHASE 2 STUDY OF TEMOZOLOMIDE (SCH 52365) IN SUBJECTS WITH ADVANCED AERODIGESTIVE TRACT CANCERS SELECTED FOR METHYLATION OF O6 METHYL-GUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER (P04273)

*AP PHARMA - A PIVOTAL PHASE 3 OBSERVER-BLIND, RANDOMIZED CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF APF530 COMPARED TO ALOXI FOR THE PREVENTION OF ACUTE-ONSET AND DELAYED-ONSET CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING FOLLOWING THE ADMINISTRATION OF EITHER MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY REGIMENS

*A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY AND EFFICACY OF SNS 595 INJECTION IN PATIENTS 60 YEARS OF AGE OR OLDER WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (SUNESIS)

EXPLORE - EXAMINATION OF PNH, BY LEVEL OF CD59 ON RED AND WHITE BLOOD CELLS, IN BONE MARROW FAILURE SYNDROMES (CLOSED TO ACCRUAL)

PROTOCOL AVF2941N: AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF METASTATIC OR LOCALLY ADVANCED AND UNRESECTABLE COLORECTAL ADENOCARCINOMA (BRITE)

LILLY B9E-US-S377 - A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND BEVACIZUMAB VERSUS GEMCITABINE, PACLITAXEL, AND BEVACIZUMAB AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC BREAST CANCER

A PHASE II STUDY OF SUNITINIB MALATE SINGLE AGENT FOR THE TREATMENT OF WOMEN WITH ADVANCED BREAST CANCER (PFIZER)

NSABP R-04 - A CLINICAL TRIAL COMPARING PREOPERATIVE RADIATION THERAPY AND CAPECITABINE WITH OR WITHOUT OXALIPLATIN WITH PREOPERATIVE RADIATION THERAPY AND CONTINUOUS INTRAVENOUS INFUSION OF 5-FLUOROURACIL WITH OR WITHOUT OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM

E5204 - INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOVORIN AND BEVACIZUMAB FOR PATIENTS WITH STAGE II OR III RECTAL CANCER RECEIVING PRE-OPERATIVE CHEMORADIATION

SWOG 9914 PHASE II TRIAL OF PACLITAXEL, CARBOPLATIN AND TOPOTECAN WITH G-CSF IN UNTREATED PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER

BCIRG 005 A MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOCETAXEL IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (TAC) VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC-T) AS ADJUVANT TREATMENT OF OPERABLE BREAST CANCER HER2NEU NEGATIVE PATIENTS WITH POSITIVE AXILLARY LYMPH NODES.

GOG 173 INTRAOPERATIVE LYMPHATIC MAPPING AND SENTINEL NODE (SN) IDENTIFICATION IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE VULVA

SWOG 9927 RANDOMIZED TRIAL OF POST-MASTECTOMY RADIOTHERAPY IN STAGE II BREAST CANCER IN WOMEN WITH ONE TO THREE POSITIVE AXILLARY NODES, PHASE III

REPIFERMIN-M04 A MULTICENTER, RISING-DOSE, RANDOMIZED, DOUBLE-BLINDED, VEHICLE-CONTROLLED STUDY OF INTRAVENOUS REPIFERMIN (KGF-S) IN SUBJECTS AT RISK OF DEVELOPING MUCOSITIS SECONDARY TO THE ACTION OF CONDITIONING REGIMENS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

REPIFERMIN-M02 A MULTICENTER, RISING-DOSE, RANDOMIZED, DOUBLE-BLINDED, VEHICLE-CONTROLLED STUDY OF INTRAVENOUS KGF-2 IN SUBJECTS AT RISK OF DEVELOPING MUCOSITIS SECONDARY TO THE ACTION OF CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

AN OPEN-LABEL, RANDOMIZED STUDY TO DEVELOP A SCREENING TOOL FOR FUNCTIONAL CAPACITY IN ANEMIC SUBJECTS WITH NONMYELOID MALIGNANCIES RECEIVING CHEMOTHERAPY AND NESP

GOG 0191 A PHASE III TRIAL TO EVALUATE THE EFFICACY OF MAINTAINING HEMOGLOBIN LEVELS ABOVE 120 G/L WITH ERYTHROPOIETIN VERSUS ABOVE 100/GL WITHOUT ERYTHROPOIETIN IN ANEMIC PATIENTS RECEIVING CONCURRENT RADIATION AND CISPLATIN FOR CERVICAL CANCER

SWOG 9412 METASTATIC BREAST CANCER RESPONDING TO CONVENTIONAL INDUCTION CHEMOTHERAPY

SWOG 9400 TREATMENT OF ADULT LYMPHOBLASTIC LEUKEMIA:A PHASE II TRIAL OF AN INDUCTION REGIMEN INCLUDING PEG-ASPARAGINASE IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FIRST COMPLETE REMISSION.

157-001 STAGE III CARCINOMA OF THE COLON - GLAXO SK-157-001

S 9630 - A RANDOMIZED COMPARISON OF MEDROXYPROGESTERONE ACETATE (MPA) AND OBSERVATION FOR PREVENTION OF ENDOMETRIAL PATHOLOGY IN POSTMENOPAUAL BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN

AMGEN-20020132 (SURPASS) -A STUDY TO ASSESS SYMPTOM BURDEN IN SUBJECTS WITH NONMYELOID MALIGNANCIES RECEIVING CHEMOTHERAPY AND ARANESP -

N 9741 - A RANDOMIZED PHASE III TRIAL OF COMBINATIONS OF OXALIPLATIN (OXAL), 5-FLUOROURACIL (5-FU), AND IRINOTECAN (CPT-11) AS INITIAL TREATMENT OF PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE COLON AND RECTUM

AMGEN-NESP 20000220 (SOAR) - AN OPEN-LABEL, RANDOMIZED STUDY TO DEVELOP A SCREENING TOOL FOR FUNCTIONAL CAPACITY IN ANEMIC SUBJECTS WITH NONMYELOID MALIGNANCIES RECEIVING CHEMOTHERAPY AND NESP

SWOG-0119 - PHASE II TRIAL OF GEMCITABINE AND IRINOTECAN IN PATIENTS WITH UNTREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC)

S 0339 - A PHASE II TRIAL OF GEMCITABINE, CARBOPLATIN AND PS-341 (NSC-681239) IN THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

NCIC-BR.1 - A PHASE III PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST, ZD1839 (IRESSA) IN COMPLETELY RESECTED PRIMARY STAGE IB, II AND IIIA NON-SMALL CELL LUNG CANCER.

S 9900 - A RANDOMIZED PHASE III TRIAL OF SURGERY ALONE OR SURGERY PLUS PREOPERATIVE PACLITAXEL/CARBOPLATIN IN CLINICAL STAGE IB (T2N0), II (T1-2N1), T3N0) and Selected III A (T3N1) NON-SMALL CELL LUNG CANCER (NSCLC)

GOG 179 A RANDOMIZED PHASE III STUDY OF CISPLATIN VERSUS CISPLATIN PLUS TOPOTECAN VERSUS MVAC (CLOSED TO PATIENT ENTRY 7/23/2001) IN STAGE IVB, RECURRENT OR PERSISTENT CARCINOMA OF THE CERVIX

AVENTIS-01024 A PROSPECTIVE... (HUMAN) CE1160 10%, COMPARED TO IMMUNE GLOBULIN INTRAVENOUS (HUMAN) GAMIMUNE N, 10% IN SUBJECTS WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

SANOFI-EFC3675 - PHASE III, RANDOMIZED, EFFICACY AND SAFETY STUDY OF COMBINATION CHEMOTHERAPY WITH TIRAPAZAMINE + CISPLATIN + VINORELBINE VERSUS CISPLATIN + VINORELBINE IN SUBJECTS WITH INOPERABLE, PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER

BMS-01124 (TAXMEN.12) A MULTICENTER, PHASE III RANDOMIZED, TRIAL FOR STAGE IIIB OR IV NON SMALL CELL LUNG CANCER (NSCLC) COMPARING WEEKLY TAXOL (PACLITAXEL) AND CARBOPLATIN (PARAPLATIN) REGIMEN VERSUS STANDARD TAXOL AND CARBOPLATIN ADMINISTERED EVERY THREE WEEKS, FOLLOWED BY WEEKLY TAXOL

N9831 - PHASE III TRIAL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS ADJUVANT TREATMENT FOR WOMEN WITH HER-2 OVEREXPRESSING NODE POSITIVE BREAST CANCER

GOG #0127-R: A PHASE II EVALUATION OF LIPOSOMAL DOXORUBICIN (DOXIL)(NSC #712227)IN THE TREATMENT OF PERSISTENT OR RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX.

SWOG-0108 - BEVACIZUMAB (RHUMAB) (NSC 704865) THERAPY FOR PATIENTS WITH RELAPSED AGGRESSIVE NON-HODGKIN'S LYMPHOMA"

S 0008 - PHASE III TRIAL OF HIGH DOSE INTERFERON ALPHA-2B VERSUS CISPLATIN, VINBLASTINE, DTIC PLUS IL-2 AND INTERFERON IN PATIENTS WITH HIGH RISK MELANOMA

SWOG-8899 - A PROSPECTIVELY RANDOMIZED TRIAL OF LOW DOSE LEUCOVORIN + 5-FU, HIGH DOSE LEUCOVORIN + 5-FU, LEVAMISOLE 5-FU, OR LOW-DOSE LEUCOVORIN + 5-FU + LEVAMISOLE FOLLOWING CURATIVE RESECTION IN SELECTED PATIENTS WITH DUKE'S B OR C COLON CANCER

SWOG-8736 -TREATMENT OF LOCALIZED NON-HODGKIN'S LYMPHOMA: COMPARISON OF CHEMOTHERAPY (CHOP) TO CHEMOTHERAPY PLUS RADIATION THERAPY, PHASE III

SWOG 8897 PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT ENDOCRINE THERAPY IN HIGH RISK, NODE NEGATIVE BREAST CANCER PATIENTS, AND A NATURAL HISTORY FOLLOW-UP STUDY IN LOW-RISK, NODE NEGATIVE PATIENTS (INTERGROUP)

S 8814 - PHASE III COMPARISON OF ADJUVNAT CHEMOENDOCRINE THERAPY WITH CAF AND CONCURRENT OR DELAYED TAMOXIFEN TO TAMOXIFEN ALONE IN POSTMENOPAUSAL PATIENTS WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS

TCON DM 92-035 POST RADIATION THERAPY PHASE III RANDOMIZED STUDY OF DFMO-PCV VERSUS PCV CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANT GLIOMAS

TCON-ID 91-025 PHASE III DOUBLE-BLIND RANDOMIZED TRIAL OF 13-CIS RETINOIC ACID (13-CRA)...PRIMARY TUMORS (SPTS) IN STAGE I NON-SMALL CELL LUNG CANCER"

TCON DM 92-017- BREAST CANCER PREVENTION TRIAL (BCPT) AMENDMENT: EXTENSION OF FOLLOW-UP TO ASSESS THE LONG-TERM OUITCOME OF THE PARTICIPANTS OF THE BCPT

SWOG-8794 - TREATMENT OF PATHOLOGIC STAGE C CARCINOMA OF THE PROSTATE WITH ADJUVANT RADIOTHERAPY

SWOG 9007 CYTOGENETIC STUDIES IN LEUKEMIA PATIENTS

SWOG 9312 PHASE II EVALUATION OF CISPLATIN + 5-FU + RADIATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED/INOPERABLE BLADDER CANCER

SWOG 9109 NEOADJUVANT ZOLADEX AND FLUTAMIDE IN BULKY AND NON-BULKY CLINICAL STAGE C CARCINOMA OF THE PROSTATE

SWOG 9304 POSTOPERATIVE EVALUATION OF 5-FU BY BOLUS INJECTION VS 5-FU BY PROLONGED VENOUS INFUSION PRIOR TO AND FOLLOWING COMBINED PROLONGED VENOUS INFUSION PLUS PELVIC XRT VS. BOLUS 5-FU PLUS...

SWOG 9205 CENTRAL PROSTATE CANCER SERUM REPOSITORY PROTOCOL

SWOG 9442 RANDOMIZED MULTI-INSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VS. BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK AND INTERMEDIATE RISK GERM CELL TUMORS

SWOG-9438 TOTAL BODY IRRADIATION, ETOPOSIDE, CYCLOPHOSPHAMIDE AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOLLOWED BY RANDOMIZATION TO THERAPY WITH INTERLEUKIN-2 VERSUS OBSERVATION FOR PATIENTS WITH NON-HODGKIN'S LYMPHOMA, A BMT STUDY, PHASE III

SWOG 9415 PHASE III RANDOMIZED TRIAL OF 5FU/LEUCOVORIN/LEVAMISOLE VERSUS 5-FU CONTINUOUS INFUSION/LEVAMISOLE AS ADJUVANT THERAPY FOR HIGH-RISK RESECTABLE COLON CANCER, INTERGROUP.

SWOG 9318 RECOMBINANT HUMAN ERYTHROPOIETIN (r-HuEPO) AS AN ADJUNCT TO RADIATION THERAPY AND CISPLATIN FOR PATIENTS WITH STAGES II-B, III-A, III-B, IV-A CARCINOMA OF THE CERVIX, PHASE II

SWOG 9349 A RANDOMIZED PHASE II TRIAL OF CHOP WITH G-CSF SUPPORT OR PROMACE-CYTABOM WITH C-CSF SUPPORT FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA

SWOG 9316 DISTRIBUTION OF RETROPERITONEAL METASTASIS POST-CHEMOTHERAPY IN PATIENTS WITH NOSEMINOMATOUS GERM CELL TUMORS.

SWOG 9405 ADEQUACY OF CONVENTIONAL RADIATION THERAPY PORTALS TO ENCOMPASS LOCALLY ADVANCED CERVIX CANCER

SWOG 8994 EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH STAGE C ADENOCARCINOMA OF THE PROSTATE

SWOG 9514 PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY

GOG 120- A RANDOMIZED COMPARISON OF HYDROXYUREA VERSUS HYDROXYUREA, 5-FU INFUSION AND BOLUS CISPLATIN VERSUS WEEKLY CISPLATIN AS ADJUNCT TO RADIATION THERAPY IN PATIENTS WITH STAGES II-B,III, IV-A CARCINOMA OF THE CERVIX AND NEGATIVE PARA-AORTIC NODES.

GOG 154 HUMAN IMMUNDEFICIENCY VIRUS (HIV) TESTING IN PATIENTS WITH INVASIVE CERVICAL CARCINOMA

GOG 109 A RANDOMIZED COMPARISON OF 5-FU INFUSION AND BOLUS CISPLATIN AS AN ADJUNCT TO RADIATION THERAPY, VERSUS RADIATION THERAPY ALONE IN SELECTED PATIENTS WITH STAGES I-A2, I-B AND II-A CARCINOMA OF THE CERIX FOLLOWING RADICAL HYSTERECTOMY AND NODE DISSECTION, PHASE III INTERGROUP.

SWOG 9403 A PHASE II STUDY OF 13-CIS RETINOIC ACID PLUS INTERFERON A-2A IN ADVANCED STAGE PENILE CARCINOMA

GOG 148 THE CLINICAL UTILITY OF SOLUBLE TNF/LT MEMBRANE RECEPTORS IN THE SERUM OF PATIENTS WITH ALL STAGES OF PRIMARY EPITHELIAL OVARIAN CANCER

SWOG 9504 PHASE II TRIAL OF CONCURRENT CISPLATIN/VP-16 AND RADIOTHERAPY FOLLOWED BY CONSOLIDATION DOCETAXEL (TAXOTERE7) IN STAGE III-B NON-SMALL CELL LUNG CANCER

SWOG 9615 NEOADJUVANT HORMONAL THERAPY PRIOR TO RADICAL PROSTATECTOMY FOR T1-2 ADENOCARCINOMA OF THE PROSTATE, PHASE III

GOG 136 ACQUISITION OF HUMAN GYNECOLOGICAL SPECIMENS AND SERUM TO BE USED IN STUDYING CANCER

GOG 141 TREATMENT OF PATIENTS WITH SUBOPTIMAL ("BULKY") STAGE IB CARCINOMA OF THE CERVIX: A RANDOMIZED COMPARISON OF RADICAL HYSTERECTOMY AND PELVIC AND PARA-AORTIC LYMPHADENECTOMY WITH OR WITHOUT NEOADJUVANT VINCRISTINE AND CISPLATIN CHEMOTHERAPY (PHASE III)

GOG 137 -A RANDOMIZED DOUBLE-BLINDED TRIAL OF ESTROGEN REPLACEMENT THERAPY VERSUS PLACEBO IN WOMEN WITH STAGE I OR II ENDOMETRIAL ADENOCARCINOMA

NSABP B-29 A CLINICAL TRIAL TO EVALUATE THE BENEFIT OF ADDING OCTREOTIDE (SMS 201-995 PA LAR) TO TAMOXIFEN ALONE OR TO TAMOXIFEN AND CHEMOTHERAPY IN PATIENTS WITH AXILLARY NODE-NEGATIVE, ESTROGEN-RECEPTOR-POSITIVE, PRIMARY INVASIVE BREAST CANCER.

GOG 76 Z LIMITED ACCESS PHASE II TRIAL OF CISPLATIN AND NAVELBINE (VINORELBINE) IN ADVANCED AND RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX

GOG 165 A RANDOMIZED COMPARISON OF RADIATION PLUS WEEKLY CISPLATIN VS RADIATION PLUS PVI (PROTRACTED VENOUS INFUSION) 5-FU IN PATIENTS WITH STAGE II-B, III-B, AND IV-A CARCINOMA OF THE CERVIX

GOG 150 - A PHASE III RANDOMIZED STUDY OF WHOLE ABDOMINAL RADIOTHERAPY (WAR) VS COMBINATION IFOSFAMIDE-MESNA WITH CISPLATIN IN OPTIMALLY DEBULKED STAGE I, II, III, OR IV CARCINOSARCOMA (CS) OF THE UTERUS

S 0023 "A PHASE III TRIAL OF CISPLATIN/ETOPOSIDE/RADIOTHERAPY WITH CONSOLIDATION DOCETAXEL FOLLOWED BY MAINTENANCE THERAPY WITH ZD1839 (NSC-715055) OR PLACEBO IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED STAGE III NON-SMALL CELL LUNG CANCER"

A RANDOMIZED, MULTI-CENTER PHASE III TRIAL OF IRINOTECAN IN COMBINATION WITH THREE DIFFERENT METHODS OF ADMINISTRATION OF FLUOROPYRIMIDINE: INFUSIONAL 5-FU (FOLFIRI), BOLUS 5-FU (DAY 1 & 8), AND ORAL CAPECITABINE (DAY 1-14); WITH CELECOXIB VERSUS PLACEBO AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER - PFIZER PHARMICIA

PHARMACOGENOMICS BLOOD SAMPLING PROTOCOL FOR IRINOTECAN/FLUOROURACIL/LEUCOVORIN (CPT-11/FU/LV) -PFIZER

S 0204 - A PHASE II TRIAL OF THALIDOMIDE/DEXAMETHASONE INDUCTION FOLLOWED BY TANDEM MELPHALAN TRANSPLANT AND PREDNISONE/THALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSD MULTIPLE MYELOMA PATIENTS, (A BMT STUDY)

S0124, "RANDOMIZED PHASE III TRIAL OF CISPLATIN AND IRINOTECAN (NSC-616348) VERSUS CISPLATIN AND ETOPOSIDE IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (E-SCLC)"

S 0002 "SMOKING CESSATION INTERVENTION (INCLUDING BUPROPION-ZYBAN VERSUS PLACEBO) FOR COMPLETELY RESECTED STAGE I AND II NON-SMALL CELL LUNG CANCER SURVIVORS WHO ARE CURRENT SMOKERS"

AMGEN-20020121 (NEULASTA) A PILOT STUDY OF THE EFFECTS OF NEUTROPENIA ON PATIENT REPORTED OUTCOMES DURING CHEMOTHERAPY WITH OR WITHOUT NEULASTA (PEGFILGRASTIM)IN SUBJECTS WITH ADVANCED NSCLC

EFFECTS OF SELECTIVE ESTROGEN RECEPTOR MODULATORS ON COGNITIVE AGING: COGNITION IN THE STUDY OF TAMOXIFEN AND RALOXIFENE (CO-STAR)

S 0012 - A COMPARATIVE RANDOMIZED STUDY OF STANDARD DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL VS. WEEKLY DOXORUBICIN AND DAILY ORAL CYCLOPHOSPHAMIDE

PLUS G-CSF FOLLOWED BY WEEKLY PACLITAXEL AS NEOADJUVANT THERAPY FOR INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER

S 0222 - A PHASE II STUDY OF TIRAPAZAMINE (NSC-130181)/CISPLATIN/ETOPOSIDE AND CONCURRENT THORACIC RADIOTHERAPY FOR LIMITED STAGE SMALL CELL LUNG CANCER

S 0205 - A PHASE III, RANDOMIZED OPEN-LABEL STUDY COMPARING GEMCITABINE PLUS CETUXIMAB (IMC-C225) VERSUS GEMCITABINE AS FIRST-LINE THERAPY OF PATIENTS WITH ADVANCED PANCREATIC CANCER

AMGEN 20010103 - A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIA OF CANCER

AMGEN 20020149 - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED ROLLOVER STUDY TO PROTOCOL 20010103 OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIA OF CANCER

GENENTECH BRITE - PROTOCOL AVF2941N: AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF METASTATIC OR LOCALLY ADVANCED AND UNRESECTABLE COLORECTAL ADENOCARCINOMA

S 0303 - A PHASE III TRIAL OF MODIFIED FOLFOX6 VS CAPOX, WITH BEVACIZUMAB (NSC-704865) OR PLACEBO, AS FIRST-LINE THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED COLORECTAL CANCER

AMGEN-20030206 SYNCHRONICITY: A STUDY TO EVALUATE THE EFFECTIVENESS OF ARANESP AT 300 MCG Q3W ON CLINICAL OUTCOMES IN CANCER PATIENTS WITH ANEMIA DUE TO CHEMOTHERAPY

S 0342 - PHASE II SELECTION DESIGN TRIAL OF CONCURRENT CHEMOTHERAPY + CETUXIMAB VS. CHEMOTHERAPY FOLLOWED BY CETUXIMAB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

NSABP B-38 - A PHASE III ADJUVANT TRIAL COMPARING THREE CHEMOTHERAPY REGIMENS IN WOMEN WITH NODE-POSITIVE BREAST CANCER: DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE (TAC); DOSE-DENSE (DD) DOXORUBICIN/CYCLOPHOSPHAMIDE FOLLOWED BY DD PACLITAXEL (DD AC/P); DD AC FOLLOWED BY DD PACLITAXEL PLUS GEMCITABINE (DD AC/PG)

AMGEN 2004 0249 - A RANDOMIZED, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL OF CHEMOTHERAPY AND BEVACIZUMAB WITH AND WITHOUT PANITUMUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH METASTATIC COLORECTAL CANCER (PACCE)

GOG 0209 - RANDOMIZED PHASE III TRIAL OF DOXORUBICIN/CISPLATIN/PACLITAXEL AND G-CSF VS CARBOPLATIN/PACLITAXEL IN PATIENTS WITH STAGE III AND IV OR RECURRENT ENDOMETRIAL CANCER

CALGB 90401] - A RANDOMIZED DOUBLE-BLINDED PLACEBO CONTROLLED PHASE III TRIAL COMPAIRING DOCETAXEL AND PREDNISONE WITH AND WITHOUT BEVACIZUMAB (IND #7921, NSC #704865) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER.

XELOX-A DVS: A RANDOMIZED STUDY OF INTERMITTENT CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX Q3W) AND BEVACIZUMAB VERSUS INTERMITTENT CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX Q2W) AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED COLORECTAL CANCER

S 0435 - A PHASE II TRIAL OF BAY 43-9006 (NSC-724772) IN PATIENTS WITH PLATINUM-TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER

E 3598- A PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, AND THORACIC RADIOTHERAPY, WITH OR WITHOUT THALIDOMIDE, IN PATIENTS WITH STAGE III NSCLC

S 0424 - MOLECULAR EPIDEMIOLOGY CASE-SERIES STUDY OF NON-SMALL CELL LUNG CANCER IN SMOKING AND NON-SMOKING WOMEN AND MEN

G 219 - A PHASE III, RANDOMIZED TRIAL OF WEEKLY CISPLATIN AND RADIATION VERSUS CISPLATIN AND TIRAPAZAMINE AND RADIATION IN STAGE IB2, IIA, IIB, IIIB AND IVA CERVICAL CARCINOMA LIMITED TO THE PELVIS

EN3267-007 - A MULTIPLE-DOSE, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF EN3267 IN THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS

RAISE (RANDOMIZED PLACEBO-CONTROLLED ITP STUDY WITH ELTROMBOPAG): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY, TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ELTROMBOPAG OLAMINE (SB-497115-GR), A THROMBOPOIETIN RECEPTOR AGONIST, ADMINISTERED FOR 6 MONTHS AS ORAL TABLETS ONCE DAILY IN ADULT SUBJECTS WITH PREVIOUSLY TREATED CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP).

SCHERING-PLOUGH - A PHASE 2 STUDY OF TEMOZOLOMIDE (SCH 52365) IN SUBJECTS WITH ADVANCED AERODIGESTIVE TRACT CANCERS SELECTED FOR METHYLATION OF O6 METHYL-GUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER (P04273)

A STUDY TO ASSESS THE EFFECTIVENESS OF PALIFERMIN ON MUCOSITIS

HYT105962 - A RANDOMIZED, PHASE III, OPEN-LABEL STUDY OF ORAL TOPOTECAN PLUS WHOLE-BRAIN RADIATION THERAPY (WBRT) COMPARED WITH WBRT ALONE IN PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER

LILLY B9E-US-S377 - A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND BEVACIZUMAB VERSUS GEMCITABINE, PACLITAXEL, AND BEVACIZUMAB AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC BREAST CANCER

YONDELIS™, ET-743 (ECTEINASCIDIN) IN SOFT TISSUE SARCOMA

A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY AND EFFICACY OF SNS 595 INJECTION IN PATIENTS 60 YEARS OF AGE OR OLDER WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (SUNESIS)

PHASE IIB, MULTICENTER, RANDOMIZED, OPEN LABEL TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS WITH UNTREATED AML 60-75 YEARS OF AGE.(CELATOR 204)

©